Annual Report and Notice of AGM

Quantum Pharma Plc

("Quantum", the "Company" or the "Group")

Annual Report and Accounts

Notice of Annual General Meeting

Retail Investor Days

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that in accordance with AIM Rule 20, electronic copies of its Annual Report and Accounts for the year ended 31 January 2016 together with the Notice of Annual General Meeting and Form of Proxy are available from the Company's investor relations website at www.quantumpharmaplc.com. Hard copies of the 2016 Annual Report and Accounts, Notice of Annual General Meeting and Form of Proxy will be posted to shareholders today.

The Company's Annual General Meeting will be held at 10:30 a.m. on Tuesday, 12 July 2016 at the offices of Muckle LLP, Time Central, 32 Gallowgate, Newcastle upon Tyne, NE1 4BF.

Retail Investor Days

Quantum Pharma is pleased to announce that it will be hosting two retail investor days in 2016. The first will be held at the Group's headquarters in Burnopfield, County Durham on Thursday, 28 July 2016 and will involve a presentation by Andrew Scaife (CEO) and Chris Rigg (CFO) followed by a tour of the facility and an opportunity to meet other members of the senior management team. The second investor day will be held in London at the offices of Buchanan, 107 Cheapside, London EC2V 6DN, on Wednesday, 30 November 2016 and this will involve a presentation by Andrew Scaife (CEO) and Chris Rigg (CFO) followed by a question and answer session.

No new material information will be made available on either of the retail investor days and copies of the presentations will be made available via the Group's investor relations website on the day of each meeting.

To register interest and receive further information on either proposed date, please email your details through to [email protected] before 20 July 2016. Places will be limited and will be offered on a first come, first served basis.

Notice of Adoption of Financial Reporting Standard 101: Reduced Disclosure Framework

The Company has also posted a letter to shareholders today, notifying shareholders of the proposed adoption of Financial Reporting Standard 101: Reduced Disclosure Framework. The text of that letter is set out below:

"Dear Shareholder,

The Company's parent company financial statements contained in the Annual Report and Accounts for the financial year ended 31 January 2016 have been prepared in accordance with UK Generally Accepted Accounting Practice (GAAP). The Financial Reporting Council (FRC) introduced a new accounting framework for the financial statements of UK companies with accounting periods commencing on or after 1 January 2015. Under this framework, Quantum Pharma Plc is required to elect to prepare its parent company financial statements on one of the bases permitted by the FRC.

The Board considers that it is in the best interests of the Group to elect to adopt FRS 101 'Reduced Disclosure Framework' for the preparation of its parent company financial statements for the year ended 31 January 2017 and on an ongoing basis until such time as shareholders are notified of any change to its chosen accounting framework for the parent company financial statements.

The adoption of FRS 101 does not require shareholder approval. However, in accordance with FRS 101, before the Company can adopt FRS 101 'Reduced Disclosure Framework', it is required to notify all shareholders of this election.

Any shareholder or shareholders holding in aggregate 5% or more of the total allotted shares in the Company may object to the adoption of FRS 101 'Reduced Disclosure Framework'. Any objections must be served in writing and delivered to the Company Secretary at Quantum House, Hobson Industrial Estate, Burnopfield, County Durham, NE16 6EA no later than 11 July 2016.

There is no need to respond to this letter unless you wish to object."

- Ends -

For further information:

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets through our Specials and Medication Adherence divisions to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.